Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$81.25 ▲ +0.59
(+0.73%)
MKT CAP: $4.48B • VOL: 483.3K
52W L $49 52W H $86
LIVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.39B | $1.25B | $1.15B |
| YoY Revenue Growth % | +10.7% | +8.7% | — |
| Gross Profit | $939.9M | $853.5M | — |
| Gross Margin % | 67.7% | 68.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $199.4M | $129.1M | -$68.5M |
| Operating Margin % | 14.4% | 10.3% | -5.9% |
| Net Income (GAAP) | -$242.5M | $63.2M | $17.6M |
| EBITDA (Normalized) | $264.2M | $166.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $254.3M | $183.0M | $74.9M |
| Capital Expenditures (CapEx) | $81.0M | $47.1M | — |
| Free Cash Flow (FCF) | $173.3M | $135.9M | $74.9M |
| FCF Margin % | 12.5% | 10.8% | 6.5% |
| Return on Invested Capital (ROIC %) | 17.3% | 7.1% | — |
| Cash & Short-Term Equivalents | $635.6M | $428.9M | — |
| Total Debt (Short + Long Term) | $345.2M | $549.6M | — |
| Total Stockholders' Equity | $1.20B | $1.32B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LIVN.